CD19/BCMA-targeted CAR-T cells is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Tongji Hospital (1) and Zhejiang University (1). Registered phase: Phase EARLY_PHASE1. Conditions studied include Relapsing or Refractory Multiple Sclerosis (MS); Myasthenia Gravis (MG); Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies (ClinicalTrials.gov ↗) Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse |
Phase EARLY_PHASE1 | Recruiting |
| NCT07337785 | CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases (ClinicalTrials.gov ↗) Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Phase EARLY_PHASE1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Relapsing or Refractory Multiple Sclerosis (MS) | 1 |
| Myasthenia Gravis (MG) | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 1 |
| Autoimmune Encephalitis (AE) | 1 |
| Multiple Myeloma in Relapse | 1 |
| Multiple Myeloma, Refractory | 1 |
| Acute Lymphoblastic Leukemia, in Relapse | 1 |
| Acute Lymphocytic Leukaemia Refractory | 1 |
| Lead sponsor | Trials |
|---|---|
| Tongji Hospital | 1 |
| Zhejiang University | 1 |
| Register | CD19/BCMA-targeted CAR-T cells trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CD19/BCMA-targeted CAR-T cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CD19/BCMA-targeted CAR-T cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.